IDEXX Laboratories Lifts Guidance on Robust Q1

Idexx Laboratories ((IDXX)) has held its Q1 earnings call. Read on for the main highlights of the call.

IDEXX Laboratories struck a decidedly upbeat tone on its latest earnings call, highlighting strong double-digit revenue growth, healthy recurring revenues, expanding margins, and powerful cash generation. Management acknowledged pockets of pressure, from softer wellness visits to rapid assay headwinds, but framed these as manageable against the backdrop of rising guidance and accelerating innovation.

Revenue Growth and Upgraded 2026 Outlook

Reported revenue climbed 14% year over year in Q1, with organic growth of 11%, underscoring resilient demand across core businesses. On the back of this performance, management raised full-year 2026 revenue guidance to $4.675–$4.76 billion, implying 8.6–10.6% reported growth and a roughly 70-basis-point uplift to organic growth at the midpoint.

CAG Diagnostics Recurring Revenue Momentum

Companion Animal Group diagnostics recurring revenue grew about 11% organically in Q1, with the U.S. advancing nearly 11% and international markets around 12%. The company now expects full-year organic CAG diagnostics recurring growth of 8.7–10.7%, driven by roughly 4% net price realization layered on top of continued volume and usage gains.

Premium Instruments and Installed Base Expansion

CAG instrument revenue surged 28% organically, fueled by the rollout of the inVue Dx platform and broader premium instrument demand. IDEXX placed roughly 1,100 inVue Dx units in the quarter and 4,650 premium instruments overall, lifting the installed base by about 12% year over year and supporting a 5,500-unit full-year inVue Dx placement goal.

Margin Expansion and EPS Upside

Comparable operating margin expanded by roughly 100 basis points in Q1, as strong top-line growth and pricing leveraged fixed costs. Comparable operating profit and EPS each rose 15%, with EPS reaching $3.47, and full-year EPS guidance was raised to $14.45–$14.90, adding $0.13 at the midpoint even after absorbing an equity-investment loss.

Recurring Consumables and Software Strength

IDEXX VetLab consumables delivered 15% organic revenue growth, powered by double-digit volume gains in both U.S. and international markets as clinics used instruments more intensively. Vet software and imaging recurring revenues also advanced 11% organically, reinforcing the company’s high-visibility, subscription-like revenue base.

Reference Labs and Diagnostic Innovation Adoption

Global reference lab revenues rose 10% organically, supported by net new customer wins and higher same-store utilization across existing clinics. Adoption of Cancer DX continued to ramp, with more than 7,500 practices ordering since launch and about 70% of North American tests run as part of panels, while new launches in Europe and Australia broadened the offering’s reach.

Record Imaging Placements and Software Momentum

Diagnostic imaging achieved a quarterly record of roughly 330 installations, helped by the DR50 PLUS launch and rising demand for integrated imaging solutions. Cloud-native practice management software installations and the Vello pet-owner engagement app both grew at double-digit rates, pointing to deeper digital integration in veterinary workflows.

Cash Generation and Capital Allocation Discipline

Free cash flow reached $234 million in Q1, and trailing 12-month conversion of net income to free cash flow stood at a robust 99%, underscoring the business’s cash efficiency. The company maintained its full-year free cash flow conversion target of 85–95% and deployed $361 million on share repurchases in the quarter, reducing diluted shares by about 2.1% year over year.

Solid Balance Sheet and FX Tailwinds

IDEXX ended the quarter with low leverage, at 0.6 times gross and 0.5 times net of cash, giving it flexibility for continued investment and shareholder returns. Foreign exchange provided a modest boost, contributing roughly $14 million to operating profit and $0.14 to EPS in Q1 after hedging, though management cautioned that currency can cut both ways.

Innovation Rollouts and Long-Term Growth Runway

The controlled rollout of inVue Dx F&A is proceeding as planned, with early customer feedback described as positive and supportive of broader menu expansion. Management emphasized a multi-year innovation roadmap spanning inVue Dx additions, Cancer DX enhancements, and new AI capabilities, coupled with stepped-up international investment, as key drivers of long-term growth.

Soft Clinical Visits and Wellness Weakness

Beneath the strong financials, the company flagged softer foot traffic in U.S. veterinary practices, with same-store clinical visits down about 1% in Q1. Wellness visits fell around 3% while non-well visits ticked up modestly, and IDEXX now assumes a roughly 1.5% decline in clinical visits for full-year 2026, signaling ongoing pressure in discretionary care.

Rapid Assay Headwinds from Platform Shift

Global rapid assay revenue was flat organically, reflecting a mix shift as clinics migrate pancreatic lipase testing from rapid assays to the Catalyst instrument platform. Management estimated this platform transition created roughly a 2% headwind to total revenue growth, but argued it ultimately strengthens recurring instrument-based revenues and enhances testing economics.

Higher Operating Expenses and One-Off Items

Reported operating expenses increased 17% year over year, or about 11% on a comparable basis, as IDEXX invested in innovation, commercialization, and international expansion. The quarter also included a $5 million loss on an equity investment and the impact of a prior litigation matter, together creating an estimated 30-basis-point drag on margins.

Supply Chain Friction in Water Business

The Water segment posted 7% organic revenue growth, showing continued demand for testing solutions across municipal and industrial customers. However, international growth slowed to the low single digits as supply chain disruptions in the Middle East constrained product availability, an issue management is working to navigate while maintaining service levels.

Placement Pacing Variability and Timing Risk

Despite reaffirming its full-year goal of 5,500 inVue Dx placements, management acknowledged that quarterly pacing can be choppy and Q1’s 1,100 placements fell below some external expectations. The company pointed to shifting customer mix between independent and corporate clinics as a driver of timing variability, suggesting near-term noise in instrument revenue but confidence in the annual target.

Macroeconomic and FX Sensitivities

IDEXX highlighted ongoing macro risks including fuel and energy price volatility, geopolitical tensions, and their potential impact on pet owner behavior and clinic visits. Currency remains a key swing factor, with management estimating that a 1% strengthening of the U.S. dollar would trim full-year revenue by about $12 million and EPS by roughly $0.04.

Raised Guidance and Forward Outlook

For 2026, IDEXX now expects $4.675–$4.76 billion in revenue, 7.7–9.7% organic growth, and 8.7–10.7% organic CAG diagnostics recurring growth, helped by roughly 4% pricing and continued volume gains. EPS guidance has been lifted to $14.45–$14.90, operating margin is projected at 32.1–32.5%, Q2 revenue is guided to grow 7.3–9.3%, and free cash flow conversion is pegged at 85–95% of net income with about $180 million in capex and an unchanged 5,500-unit inVue Dx placement goal.

IDEXX’s latest call painted a picture of a diagnostics leader using innovation, pricing power, and a growing installed base to offset softer clinic visits and isolated headwinds. For investors, the raised guidance, strong cash generation, and disciplined balance sheet support a constructive outlook, even as management remains vigilant about macro, FX, and execution risks in the quarters ahead.